MetaCap

Arbutus Biopharma Corporation Company Profile

NASDAQ: ABUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.02-0.05 (-1.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Arbutus Biopharma at a glance

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Warminster, PA, Canada. Arbutus Biopharma is led by Ms. Lindsay Androski J.D., M.B.A. and employs about 19 people. At a market capitalization of $623.9 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001447028, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Arbutus Biopharma do?

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Business description based on the company's public filings.

Company information

Legal name
Arbutus Biopharma Corporation
Ticker
NASDAQ: ABUS
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Lindsay Androski J.D., M.B.A.
Employees
19
Headquarters
701 Veterans Circle, Warminster, PA, Canada
Phone
267 469 0914
Market cap
$623.90M
SEC CIK
0001447028
Latest annual report
10-K · Mar 23, 2026

Companies similar to Arbutus Biopharma

ABUS peer companies
CompanyPrice% ChgMarket capCompare
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs ABUS
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs ABUS
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs ABUS
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs ABUS
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs ABUS
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs ABUS
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs ABUS
APMDApnimed Inc.16.09-6.70%$669.84Mvs ABUS

Related